pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Monoclonal Antibody · news · pharmadog
← back to Monoclonal Antibody
News · Monoclonal Antibody
329
stories
13h
Regeneron to challenge Ipsen as FDA clears bone disease drug
biopharma dive
17h
Regeneron wins FDA approval to challenge Ipsen for rare bone disease market
biospace
18h
Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future
biospace
20h
Chai tees up Bristol Myers Squibb AI antibody discovery collab
fiercebiotech
1d
FDA approves Regeneron’s garetosmab for disease that turns tissue to bone
endpoints
1d
Kolon TissueGene cuts 37 US staffers after Phase 3 fail
biospace
1d
Bristol Myers' partner Biokin says bispecific ADC clears fourth cancer trial in China
endpoints
1d
Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more
biospace
2d
Sandoz inks $322M Henlius deal for rights to as many as 10 biosimilars
biospace
2d
Rebounding biotech funds expected to spur CDMO growth within year
biospace
2d
Regeneron ends eye disease study due to antibody's safety profile
biospace
2d
Regeneron ends eye disease study due to antibody's safety profile
biospace
3d
Argenx jumps on Phase 3 data for blockbuster Vyvgart
biopharma dive
3d
AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer
biopharma dive
3d
AstraZeneca touts separate late-stage lung cancer wins with Tagrisso, Enhertu
endpoints
3d
Summit, Akeso's ivonescimab shows smaller benefit with longer follow-up in China
endpoints
3d
Slate, Fulcrum to combine in reverse merger
biopharma dive
3d
Summit, Akeso’s China approval celebration cut short as survival benefit degrades
biospace
3d
Regeneron ends eye disease trial for anti-CD3 antibody following safety review
fiercebiotech
3d
AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow
biospace
3d
AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow
biospace
3d
Argenx declares Phase 3 win for Vyvgart Hytrulo in autoimmune myositis
endpoints
3d
Slate uses Fulcrum to vault onto Nasdaq with $245M financing for migraine trials
fiercebiotech
3d
Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vague
fiercebiotech
4d
AstraZeneca ends phase 3 lung cancer trial after bispecific falls short versus Keytruda
fiercebiotech
6d
Biogen's monoclonal antibody felzartamab wins first global approval in China
endpoints
6d
STAT+: PBMs agree to display TrumpRx drug prices
stat
6d
MapLight presses the pause button; ADC Therapeutics considers what to do with Zynlonta
endpoints
6d
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
biopharma dive
6d
STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class
stat
← prev
page 1 of 11
next →
